Head-to-head evidence
LY900014 vs ORMD-0801
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
LY900014 · Lyumjev
Marketed by Eli Lilly
NCT03214380 · Phase 3 · completed
The study randomized and double-blinded participants to LY900014 or insulin lispro, with 933 enrolled and approximately 336-337 participants in the main comparison arms. The primary HbA1c endpoint met the prespecified non-inferiority margin, but HbA1c is a laboratory surrogate rather than a hard clinical endpoint, supporting a moderate evidence grade.
ORMD-0801
Developed by Oramed
NCT04606576 · Phase 3 · terminated
This is a large, randomized, fully blinded, placebo-controlled trial using blood sugar control (A1C), the standard disease-defining measure for diabetes, as its primary endpoint, a well-designed setup for showing a real treatment effect. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: April 2027 · NCT06731075 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: LY900014's landscape · ORMD-0801's landscape